Epidermal growth factor receptor (EGFR) is a member of the Erb-B family of transmembrane glycoprotein receptors that is aberrantly expressed in up to 80% of cases of NSCLC, and is associated with worse prognosis. Besides the anticipated statistically significant increased rate of skin rash, diarrhea, and infusion-related reactions in the cetuximab arm, febrile neutropenia was also increased (22 versus 15%; p<0.05). The primary endpoint of overall survival (OS) was improved in patients receiving the cetuximab combination (11.3 versus 10.2 months; p=0.044), with prespecified subgroup analyses suggesting a greater benefit among Caucasians independent of histology. There was no difference in overall progression-free survival (PFS). There was also no OS benefit in the Asian subgroup, although this is likely a reflection of small sample size as well as the availability of effective salvage therapies such as EGFR TK inhibitors. 
While single agents have demonstrable efficacy and less toxicity, a meta-analysis showed that doublet regimens employing modern cytotoxic agents confer a survival advantage relative to single agents. 2 Thus, among patients with good performance status, platinum-containing doublets constitute the accepted standard of care
for the first-line treatment of advanced NSCLC.
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Molecular Targeted Therapies
Epidermal growth factor receptor (EGFR) is a member of the Erb-B family of transmembrane glycoprotein receptors that is aberrantly expressed in up to 80% of cases of NSCLC, and is associated with worse prognosis. score of 0-2 whose tumors expressed EGFR. 10 Twenty-two percent of patients in each arm were non-smokers, and patients of Caucasian descent accounted for over 80% of the intake in each arm. The trial was conducted at 166 centers worldwide, including Europe, South America, and Asia.
Besides the anticipated statistically significant increased rate of skin rash, diarrhea, and infusion-related reactions in the cetuximab arm, febrile neutropenia was also increased (22 versus 15%; p<0.05). The primary endpoint of overall survival (OS) was improved in patients receiving the cetuximab combination (11.3 versus 10.2 months; p=0.044), with prespecified subgroup analyses suggesting a greater benefit among Caucasians independent of histology. There was no difference in overall progression-free survival (PFS). There was also no OS benefit in the Asian subgroup, although this is likely a reflection of small sample size as well as the availability of effective salvage therapies such as EGFR TK inhibitors. where there was no OS benefit with the addition of bevacizumab. 15 The similarly designed phase III placebo-controlled European Avastin in Lung Cancer (AVAIL) trial combined bevacizumab at two different doses (7.5 and 15mg/kg) with cisplatin and gemcitabine followed by maintenance bevacizumab treatment. The study met its primary endpoint with a median PFS of 6.1 months in the chemotherapy group compared with 6.7 months (p=0.003) and 6.5 months (p=0.03) in the low-and high-dose bevacizumab groups, respectively. 16 While median survival of patients in all arms of the study exceeded one year, there was no statistically significant difference in OS among the treatment arms. 
Cytotoxic Agents
Albumin-bound paclitaxel (Abraxane ® ) is a Cremophor ® -free, albuminbound particle form of paclitaxel that has shown promising phase II results in first-line advanced NSCLC. 29 There is an ongoing registrational phase III trial that will randomize approximately 1,000 patients to carboplatin with albumin-bound paclitaxel or paclitaxel, with response rate as the primary end-point. Emerging data on the histological subtype of NSCLC influencing treatment outcomes have provoked much levels (cislatin/docetaxel for patients with low ERCC1 levels; docetaxel/ gemcitabine for patients with high ERCC1 levels). 34 Response rates were statistically higher in the genotypic arm. However, no differences were seen in survival outcomes due to technical and design issues. This study represents a pioneering effort in the establishment of 'molecularly tailored' individualized therapy. 
Conclusions
